{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:22Z","timestamp":1791925342672,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"29","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,7,16]]},"DOI":"10.1038\/s41388-020-1352-y","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T08:03:26Z","timestamp":1592294606000},"page":"5214-5227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9752-983X","authenticated-orcid":false,"given":"Yu-Hang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-0952","authenticated-orcid":false,"given":"Wen-Na","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-8057","authenticated-orcid":false,"given":"Shu-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0614-6188","authenticated-orcid":false,"given":"Rong-Rong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-4769","authenticated-orcid":false,"given":"Shi-Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-9729","authenticated-orcid":false,"given":"Dong-Dong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-572X","authenticated-orcid":false,"given":"Sheng-Biao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-4342","authenticated-orcid":false,"given":"Zhi-Kun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-6539","authenticated-orcid":false,"given":"Wen-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-4361","authenticated-orcid":false,"given":"Xin-Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4466-6045","authenticated-orcid":false,"given":"Shu-Xiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-4381","authenticated-orcid":false,"given":"Xian-Jun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"1352_CR1","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"1352_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jval.2011.07.008","volume":"15","author":"A Manca","year":"2012","unstructured":"Manca A, Asseburg C, Bravo VY, Seymour MT, Meade A, Stephens R, et al. The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). Value Health. 2012;15:22\u201331.","journal-title":"Value Health"},{"key":"1352_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","volume":"370","author":"MT Seymour","year":"2007","unstructured":"Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143\u201352.","journal-title":"Lancet"},{"key":"1352_CR4","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1158\/1078-0432.CCR-11-0304","volume":"17","author":"S Afzal","year":"2011","unstructured":"Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, Broedbaek K, et al. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res. 2011;17:3822\u20139.","journal-title":"Clin Cancer Res"},{"key":"1352_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0925-4439(02)00082-0","volume":"1587","author":"GJ Peters","year":"2002","unstructured":"Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587:194\u2013205.","journal-title":"Biochim Biophys Acta"},{"key":"1352_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0378-1119(96)00445-3","volume":"180","author":"N Hamajima","year":"1996","unstructured":"Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene. 1996;180:157\u201363.","journal-title":"Gene"},{"key":"1352_CR7","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-12-3858","volume":"73","author":"SM Offer","year":"2013","unstructured":"Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013;73:1958\u201368.","journal-title":"Cancer Res"},{"key":"1352_CR8","first-page":"dju298.","volume":"106","author":"AM Lee","year":"2014","unstructured":"Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106:dju298.","journal-title":"J Natl Cancer Inst"},{"key":"1352_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrm1103","volume":"4","author":"S Spiegel","year":"2003","unstructured":"Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397\u2013407.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1352_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1128\/EC.4.1.178-189.2005","volume":"4","author":"J Min","year":"2005","unstructured":"Min J, Traynor D, Stegner AL, Zhang L, Hanigan MH, Alexander H, et al. Sphingosine kinase regulates the sensitivity of Dictyostelium discoideum cells to the anticancer drug cisplatin. Eukaryot Cell. 2005;4:178\u201389.","journal-title":"Eukaryot Cell"},{"key":"1352_CR11","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1182\/blood-2010-08-300772","volume":"117","author":"A Salas","year":"2011","unstructured":"Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011;117:5941\u201352.","journal-title":"Blood"},{"key":"1352_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1158\/1078-0432.CCR-12-1050","volume":"19","author":"R Rosa","year":"2013","unstructured":"Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D\u2019Amato C, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 2013;19:138\u201347.","journal-title":"Clin Cancer Res"},{"key":"1352_CR13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.1176709","volume":"325","author":"NC Hait","year":"2009","unstructured":"Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325:1254\u20137.","journal-title":"Science"},{"key":"1352_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3389\/fphar.2019.00807","volume":"10","author":"S Grassi","year":"2019","unstructured":"Grassi S, Mauri L, Prioni S, Cabitta L, Sonnino S, Prinetti A, et al. Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases. Front Pharm. 2019;10:807.","journal-title":"Front Pharm"},{"key":"1352_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuropharm.2016.11.006","volume":"113","author":"S O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan S, Dev KK. Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases. Neuropharmacology. 2017;113:597\u2013607.","journal-title":"Neuropharmacology"},{"key":"1352_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.109.163444","volume":"333","author":"KJ French","year":"2010","unstructured":"French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharm Exp Ther. 2010;333:129\u201339.","journal-title":"J Pharm Exp Ther"},{"key":"1352_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10787-010-0060-6","volume":"19","author":"LR Fitzpatrick","year":"2011","unstructured":"Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang Y, Maines LW, et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology. 2011;19:75\u201387.","journal-title":"Inflammopharmacology"},{"key":"1352_CR18","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1535-7163.MCT-15-0279","volume":"14","author":"H Venant","year":"2015","unstructured":"Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, et al. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Mol Cancer Ther. 2015;14:2744\u201352.","journal-title":"Mol Cancer Ther"},{"key":"1352_CR19","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-16-2363","volume":"23","author":"CD Britten","year":"2017","unstructured":"Britten CD, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, et al. A Phase I Study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017;23:4642\u201350.","journal-title":"Clin Cancer Res"},{"key":"1352_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1042\/BJ20120609","volume":"447","author":"Y Kharel","year":"2012","unstructured":"Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, Lynch KR, et al. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J. 2012;447:149\u201357.","journal-title":"Biochem J"},{"key":"1352_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","volume":"23","author":"J Liang","year":"2013","unstructured":"Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23:107\u201320.","journal-title":"Cancer Cell"},{"key":"1352_CR22","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1200\/JCO.2002.20.6.1683","volume":"20","author":"AA Adjei","year":"2002","unstructured":"Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, et al. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002;20:1683\u201391.","journal-title":"J Clin Oncol"},{"key":"1352_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-4347(00)00377-7","volume":"750","author":"G Micoli","year":"2001","unstructured":"Micoli G, Turci R, Arpellini M, Minoia C. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001;750:25\u201332.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1352_CR24","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.1073\/pnas.1000478107","volume":"107","author":"OM Dovey","year":"2010","unstructured":"Dovey OM, Foster CT, Cowley SM. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci USA. 2010;107:8242\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1352_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"M Maceyka","year":"2012","unstructured":"Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50\u201360.","journal-title":"Trends Cell Biol"},{"key":"1352_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1535-7163.MCT-08-1096","volume":"8","author":"J Guillermet-Guibert","year":"2009","unstructured":"Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther. 2009;8:809\u201320.","journal-title":"Mol Cancer Ther"},{"key":"1352_CR27","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1016\/j.febslet.2005.08.055","volume":"579","author":"S Sarkar","year":"2005","unstructured":"Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, Milstien S, et al. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. Febs Lett. 2005;579:5313\u20137.","journal-title":"Febs Lett"},{"key":"1352_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/gutjnl-2013-306571","volume":"64","author":"D Rosmarin","year":"2015","unstructured":"Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64:111\u201320.","journal-title":"Gut"},{"key":"1352_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens J, Swen JJ, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharm Ther. 2018;103:210\u20136.","journal-title":"Clin Pharm Ther"},{"key":"1352_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13046-015-0205-y","volume":"34","author":"C Xun","year":"2015","unstructured":"Xun C, Chen MB, Qi L, Tie-Ning Z, Peng X, Ning L, et al. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J Exp Clin Cancer Res. 2015;34:94.","journal-title":"J Exp Clin Cancer Res"},{"key":"1352_CR31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1080\/15384047.2017.1345396","volume":"18","author":"ER Camp","year":"2017","unstructured":"Camp ER, Patterson LD, Kester M, Voelkel-Johnson C. Therapeutic implications of bioactive sphingolipids: a focus on colorectal cancer. Cancer Biol Ther. 2017;18:640\u201350.","journal-title":"Cancer Biol Ther"},{"key":"1352_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/978-1-4939-3603-8_26","volume":"1422","author":"B Parang","year":"2016","unstructured":"Parang B, Barrett CW, Williams CS. AOM\/DSS model of colitis-associated cancer. Methods Mol Biol. 2016;1422:297\u2013307.","journal-title":"Methods Mol Biol"},{"key":"1352_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.prp.2014.06.016","volume":"210","author":"C Sun","year":"2014","unstructured":"Sun C, Zargham R, Shao Q, Gui X, Marcus V, Lazaris A, et al. Association of CD98, integrin beta1, integrin beta3 and Fak with the progression and liver metastases of colorectal cancer. Pathol Res Pr. 2014;210:668\u201374.","journal-title":"Pathol Res Pr"},{"key":"1352_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/ni.2117","volume":"12","author":"BL Kidder","year":"2011","unstructured":"Kidder BL, Hu G, Zhao K. ChIP-Seq: technical considerations for obtaining high-quality data. Nat Immunol. 2011;12:918\u201322.","journal-title":"Nat Immunol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1352-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:21:19Z","timestamp":1684617679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-1352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":34,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2020,7,16]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-1352-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}